All lobbying filings

MEHLMAN CONSULTING, INC.

Lobbying for THE CAMPAIGN FOR SUSTAINABLE RX PRICING · A coalition of organizations working on market-based solutions to drug pricing.

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 17, 2025

Income

$90,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 1

JOSEPH EDWARD BROWN III New on this filing

Previously held: Sr Prof Staff (EPW Comm Maj/Sen. Moore Capito); Prof Staff (EPW Comm Min/Ranking Mem Sen. Moore Capito); Leg Asst (Sen. Boozman); Maj Leg Asst (EPW Comm Maj/Sen. Jim Inhofe); Maj Research Asst (EPW Comm Maj/Sen. Jim Inhofe); Intern (Rep. Jim Renacci)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 4

Centers For Medicare and Medicaid Services (CMS)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 23

S 229
DTC Act of 2025
HR 3789
DTC Act of 2025
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 1032
Major Richard Star Act
S 1954
Biosimilar Red Tape Elimination Act
S 1095
Stop STALLING Act
S 1067
Ensuring Timely Access to Generics Act of 2023
S 2630
Saving NSF’s Workforce Act
S 1040
Drug Competition Enhancement Act
S 1041
Affordable Prescriptions for Patients Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
S 1097
Interagency Patent Coordination and Improvement Act of 2025
S 43
Skinny Labels, Big Savings Act
HR 3269
ETHIC Act
S 2276
ETHIC Act
S 2658
Medication Affordability and Patent Integrity Act
HR 3160
PREVAIL Act
S 1533
A bill to amend title 38, United States Code, to make permanent and codify the pilot program for use of contract physic…
HR 3152
Patent Eligibility Restoration Act of 2025
S 1546
Patent Eligibility Restoration Act of 2025
HR 3010
No Handouts for Drug Advertisements Act
S 1785
No Handouts for Drug Advertisements Act

Lobbying activity 3

Medicare/Medicaid

Prescription drug pricing issues. S. 229 Drug-price Transparency for Consumers (DTC) Act. H.R. 3789 - The Drug-price Transparency for Consumers (DTC) Act. H.R. 1/PL 119-21 - One Big Beautiful Bill Act.

Pharmacy

Prescription drug pricing issues. H.R. 1843/S. 1032 - Increasing Transparency in Generic Drug Applications Act. S. 1954 - Biosimilar Red Tape Elimination Act; S. 1095 - Stop Stalling Act S. 1067 - Ensuring Timely Access to Generics Act; S. 2630 - REMEDY Act

Patent abuse issues. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.1096 - Preserve Access to Affordable Generics and Biosimilars Act. S.1095 - Stop STALLING Act. S. 1097 - Interagency Patent Coordination and Improvement Act of 2025. S. 43 - Skinny Labels, Big Savings Act. H.R. 3269/S. 2276 - ETHIC Act. S. 2658 - Medication Affordability and Patent Integrity Act. H.R. 3160/s. 1533 - the Prevail Act. H.R. 3152/S. 1546 - Patient Eligibility Restoration Act. H.R. 3010/S. 1785 - the No Handouts for Drug Advertisement Act.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.